Switch theme
Sign up to access all valuation multiples
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
1994
270
LTM Revenue n/a
LTM EBITDA n/a
$95.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Intercure has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Intercure achieved revenue of $356M and an EBITDA of -$23.9M.
Intercure expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Intercure valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $389M | $356M | XXX | XXX | XXX |
| Gross Profit | $91.1M | $155M | XXX | XXX | XXX |
| Gross Margin | 23% | 44% | XXX | XXX | XXX |
| EBITDA | $70.2M | -$23.9M | XXX | XXX | XXX |
| EBITDA Margin | 18% | -7% | XXX | XXX | XXX |
| Net Profit | $4.7M | $44.8M | XXX | XXX | XXX |
| Net Margin | 1% | 13% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Intercure's stock price is $1.
Intercure has current market cap of $60.4M, and EV of $95.4M.
See Intercure trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $95.4M | $60.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Intercure has market cap of $60.4M and EV of $95.4M.
Intercure's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Intercure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Intercure and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $95.4M | XXX | XXX | XXX |
| EV/Revenue | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | -4.0x | XXX | XXX | XXX |
| P/E | -1.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpIntercure's NTM/LTM revenue growth is n/a
Intercure's revenue per employee for the last fiscal year averaged $1.3M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Intercure's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Intercure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Intercure and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -7% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -134% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 19% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Intercure acquired XXX companies to date.
Last acquisition by Intercure was XXXXXXXX, XXXXX XXXXX XXXXXX . Intercure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Intercure founded? | Intercure was founded in 1994. |
| Where is Intercure headquartered? | Intercure is headquartered in United States of America. |
| How many employees does Intercure have? | As of today, Intercure has 270 employees. |
| Who is the CEO of Intercure? | Intercure's CEO is Mr. Alexander Rabinovich. |
| Is Intercure publicy listed? | Yes, Intercure is a public company listed on NAS. |
| What is the stock symbol of Intercure? | Intercure trades under INCR ticker. |
| When did Intercure go public? | Intercure went public in 2019. |
| Who are competitors of Intercure? | Similar companies to Intercure include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Intercure? | Intercure's current market cap is $60.4M |
| What is the current revenue growth of Intercure? | Intercure revenue growth between 2023 and 2024 was -9%. |
| Is Intercure profitable? | Yes, Intercure is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
